MihaelaCristeaMD

Oncology • Duarte, CA

Associate Professor

Join to view full profile

Dr. Cristea is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cristea's full profile

Already have an account?

Office
1500 E Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111
Is this information wrong?

Education & Training

University of Florida College of Medicine JacksonvilleFellowship, Hematology and Medical Oncology, 1998 - 2000
Rutgers Health/Monmouth Medical CenterResidency, Internal Medicine, 1995 - 1998
University of Medicine and Pharmacy ‘Gr T Popa” Iasi Class of 1992

Certifications & Licensure

NC State Medical License 2000 - Present
CA State Medical License 2004 - 2024
FL State Medical License 1999 - 2006
MI State Medical License 1997 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity Start of enrollment: 2009 Jan 01
Completed
Phase 1
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Start of enrollment: 2012 Dec 03
Completed
Phase 2
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Start of enrollment: 2013 Apr 29
Active, not recruiting
Phase 2
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Start of enrollment: 2017 Mar 22
Completed
Phase 1
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2018 Feb 01
Active, not recruiting
Phase 2
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Start of enrollment: 2019 Jul 03
Suspended
Phase 1
Join now to see all

Publications & Presentations

PubMed

Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Antons Martincuks, Chunyan Zhang, Theresa Austria, Yi-Jia Li, Rui Huang, Nicole Lugo Santiago, Adrian Kohut, Qianqian Zhao, Rosemarie Martinez Borrero, Binghui Shen, H...> ;Journal for Immunotherapy of Cancer. 2024 Apr 5
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer...
Mihaela C Cristea, Daphne Stewart, Timothy Synold, Nora Ruel, Joanne Mortimer, Edward Wang, Alexander Jung, Sharon Wilczynski, Gottfried E Konecny, Melissa Eng, Lindsa...> ;Gynecologic Oncology. 2024 Mar 1
Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
Ferdynand J Kos, Paul Frankel, Mihaela Cristea, Melissa Eng, Raechelle Tinsley, Shannon Dempsey, Nora Ruel, Thanh H Dellinger, Don J Diamond, Stewart, D.> ;Cancer Research Communications. 2023 Dec 20
3 citations
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting.
Eric Hee Jun Lee, John P Murad, Lea Christian, Jackson Gibson, Yukiko Yamaguchi, Cody Cullen, Diana Gumber, Anthony K Park, Cari Young, Isabel Monroy, Jason Yang, Lawr...> ;Nature Communications. 2023 Aug 7
Care Processes and Quality-of-Life Outcomes Affecting the Gynecologic Cancer Survivorship Experience.
Anne M Reb, Denice Economou, Diane G Cope, Tami Borneman, Maribel S Tejada, Ernest S Han, Mihaela Cristea, Betty R Ferrell> ;Oncology Nursing Forum. 2023 Feb 17
BRCA germline mutations in multiethnic gynecologic patients: A 10-year retrospective analysis from a single cancer institute.
Christina H Wei, Susan Shehayeb, Nicole Lugo Santiago, Laura Kruper, Ernest Han, Edward Wang, Mihaela Cristea, Lorna Rodriguez-Rodriguez, Susan E Yost, Daphne Stewart> ;Plos One. 2023 Jan 1
87 citations
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Deborah K Armstrong, Ronald D Alvarez, Floor J Backes, Jamie N Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-May Chen, Viola C Chitiyo, Mihaela Cr...> ;Journal of the National Comprehensive Cancer Network. 2022 Sep 1
Leveraging an Informatics Approach to Identify an Unmet Clinical Need for/Testing Among Patients With Ovarian Cancer.
Stacy W Gray, Rebecca A Ottesen, Madeline Currey, Mihaela Cristea, Janet Nikowitz, Susan Shehayeb, Vanessa Lozano, Julie Hom, Julie Kilburn, Lisa N Lopez, Sam Wing, Er...> ;JCO Clinical Cancer Informatics. 2022 Sep 1
10 citations
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a...
John Hilton, Mihaela Cristea, Sophie Postel-Vinay, Capucine Baldini, Mark Voskoboynik, William Edenfield, Geoffrey I Shapiro, Michael L Cheng, Jacqueline Vuky, Bradley...> ;Cancers. 2022 Aug 23
1 citations
Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management.
Betty R Ferrell, Nora Ruel, Tami Borneman, Marianna Koczywas, Mihaela Cristea> ;Clinical Journal of Oncology Nursing. 2022 Apr 1
11 citations
Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.
Thanh H Dellinger, Ernest S Han, Mustafa Raoof, Byrne Lee, Xiwei Wu, Hyejin Cho, Ting-Fang He, Peter Lee, Marianne Razavi, Winnie S Liang, Daniel Schmolze, Saul J Pric...> ;JCO Precision Oncology. 2022 Mar 1
7 citations
Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging?
Colton Ladbury, Richard Li, Jay C. Shiao, Jason Liu, Mihaela C. Cristea, Ernest S. Han, Thanh H. Dellinger, Stephen J. Lee, Edward Wang, Christine M. Fisher, Yi-Jen Ch...> ;Gynecologic Oncology. 2021 Nov 15
10 citations
PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.
, , , , , , , , , , , , , , , , , , > ;Annals of Surgical Oncology. 2021 Aug 13
5 citations
Recall of Genomic Testing Results Among Patients with Cancer.
Sam E. Wing, Hengrui Hu, Lisa Lopez, Ilana Solomon, Jenny Shen, Catherine Raquel, Melissa Sur, Joseph Chao, Mihaela C. Cristea, Joanne E. Mortimer, Sumanta K. Pal, Kar...> ;The Oncologist. 2021 Aug 26
8 citations
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients.
, , , , , , , , , , , , , , , , , , , , , , , , , > ;Cancers. 2021 Jun 3
20 citations
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Aritro Nath, Patrick A. Cosgrove, Hoda Mirsafian, Elizabeth L. Christie, Lance Pflieger, Benjamin Copeland, Sumana Majumdar, Mihaela C. Cristea, Ernest S. Han, Stephen...> ;Nature Communications. 2021 May 24
13 citations
Germline mutations and age at onset of lung adenocarcinoma.
Karen L. Reckamp, Carolyn E. Behrendt, Thomas P. Slavin, Stacy W. Gray, Danielle Castillo, Marianna Koczywas, Mihaela C. Cristea, Kirsten M. Babski, Donna Stearns, Cat...> ;Cancer. 2021 Aug 1
10 citations
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer...
Athanassios Argiris, Jieling Miao, Mihaela C. Cristea, Allen M. Chen, Jacob Sands, Roy H. Decker, Scott N. Gettinger, Megan E. Daly, Bryan A. Faller, Kathy S. Albain, ...> ;Clinical Lung Cancer. 2021 Feb 19
300 citations
Ovarian cancer, version 2.2020
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela C. Cristea, Maria DeRosa, Eric L...> ;Journal of the National Comprehensive Cancer Network. 2021 Feb 2
98 citations
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux, Mihaela C. Cristea, Jeff Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B. Olawaiye, Susan Ellard, Johanne I Weberpals, Andre...> ;Lancet. 2021 Jan 23
13 citations
PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer.
Antons Martincuks, Jieun Song, Adrian Kohut, Chunyan Zhang, Yi-Jia Li, Qianqian Zhao, Edward Mak, Lorna Rodriguez-Rodriguez, Hua Yu, Mihaela Cristea> ;Frontiers in Oncology. 2021 Jan 1
6 citations
A nurse-led intervention for fear of cancer progression in advanced cancer: A pilot feasibility study.
Anne Reb, Tami Borneman, Denice Economou, Marissa A. Cangin, Diane G. Cope, Huiyan Ma, Nora Ruel, Louise Sharpe, Sunita K. Patel, Mihaela C. Cristea, Marianna Koczywas...> ;European Journal of Oncology Nursing. 2020 Oct 7
11 citations
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Erika Hamilton, David M. O'Malley, Roisin E. O'Cearbhaill, Mihaela C. Cristea, Gini F. Fleming, Bilal Tariq, Abraham Fong, Dorothy French, Michael Rossi, Daniel Brickm...> ;Gynecologic Oncology. 2020 Sep 1
3 citations
Frontline Management of Epithelial Ovarian Cancer-Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research.
Edward Wang, Christina Hsiao Wei, Sariah Liu, Stephen J. Lee, Susan Shehayeb, Scott Glaser, Richard Li, Siamak Saadat, James Shen, Thanh H. Dellinger, Ernest S. Han, D...> ;Journal of Clinical Medicine. 2020 Sep 1
15 citations
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C. Dhani, Hal W. Hirte, Lisa Wang, Julia V. Burnier, Angela Jain, Marcus O. Butler, Stephen Welch, Gini F. Fleming, Jean A. Hurteau, Koji Matsuo, Daniela Matei,...> ;Clinical Cancer Research. 2020 Jun 1
Join now to see all

Lectures

A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC),...
2019 ASCO Annual Meeting - 6/1/2019